Natco Pharma
- Company typePublic
- Founded2023
- HeadquartersHyderabad, India
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
Natco Pharma firmographics
Firmographics- Name
- Natco Pharma
- Legal name
- Natco Pharma Limited
- Website
- https://natcopharma.co.in
- Company type
- Public
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Ownership category
- akta.pro rank
Natco Pharma industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro industry
- Contract Development & Manufacturing for Generics (CDMO/CMO)Specialty Pharmaceutical Distributors
Keywords
Where Natco Pharma is headquartered
LocationHeadquarters
- HQ city
- Hyderabad
- HQ country
- India
- HQ region
- Asia
Offices3 records
Markets served
Natco Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Sales - US Market: Revenue from generic drug sales in US market through ANDA approvals and partnerships with Lupin and Breckenridge. Key products include Pomalidomide and Eribulin Mesylate.
- Pharmaceutical Sales - Domestic India: Revenue from domestic pharmaceutical sales in India including Semaglutide injection for diabetes and weight management. Company operates through partnerships for distribution.
- Agrochemicals: Agrochemicals business contributing approximately Rs 60.62 crore (1.48% of total turnover) in FY2024-25. The segment is being demerged into Natco Crop Health Sciences Limited.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Monthly | Semaglutide Injection Multi-dose Vials - Rs 1,290 per month |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels2 records
Natco Pharma product offering
Product offeringCore offering
Natco Pharma manufactures and markets affordable generic pharmaceutical products, with a strategic focus on complex formulations including oncology drugs, peptide-based injectables (Semaglutide), and specialty medicines. The company operates across India and the US through ANDA approvals and strategic alliance partnerships with established pharmaceutical distributors.
Product overview
Natco Pharma operates as a pharmaceutical company with two main business segments: pharmaceuticals and agrochemicals. The pharmaceutical segment includes generic formulations for oncology, diabetes management, and specialty medicines, with key products including Semaglutide Injection (diabetes/weight management), Pomalidomide Capsules (multiple myeloma), and Eribulin Mesylate Injection (breast cancer). The company has strategic alliances with Lupin (Eribulin Mesylate), Breckenridge Pharmaceutical (Pomalidomide), and Eris Lifesciences (Semaglutide). The agrochemicals segment, planned for demerger, contributed approximately 1.48% of revenue.
Differentiator
Problem solved
Functional benefit
Products and services
- Semaglutide Injection Generic semaglutide injection for Type 2 diabetes treatment and weight management. Approved by CDSCO and launched in India following patent expiry of Novo Nordisk's Ozempic/Wegovy. Available in multi-dose vials and pen device formats.
- Pomalidomide Capsules Generic version of Celgene's Pomalyst for treatment of multiple myeloma, AIDS-related Kaposi sarcoma, and Kaposi sarcoma. Launched in US market in partnership with Breckenridge Pharmaceutical Inc.
- Eribulin Mesylate Injection Generic version of Eisai's Halaven Injection for treatment of adults with metastatic breast cancer and unresectable or metastatic liposarcoma. USFDA-approved through alliance with Lupin.
- Agrochemicals Business Natco's agrochemicals division approved for demerger into Natco Crop Health Sciences Limited, with appointed date of October 1, 2026. Contributed Rs 60.62 crore (1.48% of total turnover) in FY2024-25.
Companies that use Natco Pharma
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles4 records
Natco Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Natco Pharma partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- LupincoreAlliance partnership with Lupin for US market commercialization of Eribulin Mesylate Injection, a generic version of Eisai's Halaven. Both companies received US FDA approval for the abbreviated new drug application (ANDA). The drug is indicated for adults with metastatic breast cancer and unresectable or metastatic liposarcoma.
- Breckenridge Pharmaceutical InccorePartnership with Breckenridge Pharmaceutical Inc for launch of Pomalidomide capsules in US market. The generic version of Celgene's Pomalyst is used for treatment of multiple myeloma and AIDS-related Kaposi sarcoma. Natco expects 180 days of shared exclusivity.
- Eris LifesciencescorePartnership with Eris Lifesciences for distribution of generic Semaglutide injection in India following patent expiry of Novo Nordisk's Ozempic. Natco received CDSCO approval on February 14, 2026, and launched at Rs 1,290 per month as the most affordable GLP-1 option in the market.
Scale indicators6 records
Recent moves9 records
Expansion highlights6 records
Natco Pharma competitors and assessment
Company assessmentDirect peers
- Lupin: Lupin is one of India's largest generic pharmaceutical manufacturers with a significant US generics business and is a direct competitor; it is also Natco's US distribution partner for Eribulin Mesylate, making it the closest comparable on complex generics, ANDA portfolio, and US channel strategy.
- Aurobindo Pharma: Aurobindo is a leading Indian generic manufacturer with a broad US ANDA portfolio and oncology presence, making it a direct peer on complex generic strategy, US regulatory execution, and emerging-market expansion.
- Dr. Reddy's Laboratories: Dr. Reddy's is a direct peer in complex generics, specialty oncology injectables, and US-India dual-market strategy, with overlapping ANDA pipelines and similar partnership-driven distribution approaches.
- Sun Pharmaceutical Industries: Sun Pharma is India's largest specialty/generic manufacturer with a strong US presence and a deep oncology and complex-generic portfolio, making it a direct peer across Natco's primary therapeutic and geographic focus areas.
- Cipla: Cipla is a direct peer as an Indian-origin generic manufacturer with significant US revenue, complex respiratory and oncology generics, and emerging-market distribution strength.
- Zydus Lifesciences (Cadila Healthcare): Zydus is a direct peer in Indian generics manufacturing, US ANDA filings, and specialty/oncology formulations, with similar partnership models and emerging-market expansion priorities.
- Glenmark Pharmaceuticals: Glenmark is a direct peer in Indian complex generics, US ANDA commercialization, and specialty drug launches, with comparable product mix in dermatology, oncology, and respiratory.
Broad incumbents
- Teva Pharmaceutical Industries: Teva is the world's largest generic manufacturer and a broad incumbent in US specialty generics, particularly oncology, providing a benchmark for pricing erosion, exclusivity strategies, and partnership economics that affect Natco's US launches.
- Viatris (Mylan): Viatris is a broad incumbent in global generic and specialty pharmaceuticals with a deep US ANDA portfolio and established distribution; it competes with Natco's US partners and represents a likely competitor on Pomalidomide and other ANDA assets.
Emerging players
- Eris Lifesciences: Eris Lifesciences is Natco's domestic India distribution partner for Semaglutide and an emerging specialty pharma player in diabetes and cardiology; it is comparable as a channel partner/peer in the Indian specialty generics space where Natco is expanding.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Natco Pharma social profiles
Digital presenceNatco Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Natco Pharma leadership team
Management profileNumber of profiles
Profiles3 records
Natco Pharma subsidiaries and ownership
Company hierarchySubsidiaries5 records
Natco Pharma funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Natco Pharma M&A and investment
M&A and investmentM&A1 record
Investments7 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Natco Pharma
What does Natco Pharma do?
Natco Pharma manufactures and markets affordable generic pharmaceutical products, with a strategic focus on complex formulations including oncology drugs, peptide-based injectables (Semaglutide), and specialty medicines. The company operates across India and the US through ANDA approvals and strategic alliance partnerships with established pharmaceutical distributors.
Is Natco Pharma a public or private company?
Natco Pharma is a public company. It is classified as public and is currently operating.
When was Natco Pharma founded?
Natco Pharma was founded in 2023. It employs 1,001 to 5,000 people.
Where is Natco Pharma based?
Natco Pharma is headquartered in Hyderabad, India, in the Asia region.
How does Natco Pharma make money?
Three revenue lines are on record. Pharmaceutical Sales - US Market is the primary driver. The others are pharmaceutical Sales - Domestic India and agrochemicals.
Who are Natco Pharma's main competitors?
Direct peers on record are Lupin, Aurobindo Pharma, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, Cipla, Zydus Lifesciences (Cadila Healthcare) and Glenmark Pharmaceuticals. Broad incumbents are Teva Pharmaceutical Industries and Viatris (Mylan). Eris Lifesciences is listed as an emerging player.
Does Natco Pharma have an API?
No public API is recorded for Natco Pharma.
What industry is Natco Pharma in?
Natco Pharma's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO), with a secondary code of HLAIAJAB, Specialty Pharmaceutical Distributors. Its NAICS code is 325412 and its SIC code is 2834.